斑头雁(Anser indicus)高铁血红蛋白的晶体生长和初步的X-射线衍射研究

本文报导了斑头雁(Auser indicus)高铁血红蛋白的晶体生长和初步的晶体学研究.晶体的衍射分辨率为2.5A或更好,四方晶系.空间群为P4:2_12,晶胞参数为:a=b=80.8A,e=107.3A,V=700523A~3.每个晶胞中含4个四聚体分子,每个不对称单位中含半个四聚体分子.     

携带人肝细胞生长因子重组质粒pUDK-HGF对大鼠肾纤维化的防治作用

目的:研究肝细胞生长因子(HGF)基因转导对庆大霉素诱导的大鼠肾纤维化损伤的防治效果。方法:以雄性Wistar大鼠腹腔注射硫酸庆大霉素注射液制备肾纤维化模型;实验分为正常对照组、肾纤维化模型组、HGF治疗组;造模后第30 d,HGF治疗组于左侧肾脏直接注射重组质粒pUDK-HGF注射液,模型组注射质粒pUDK,正常对照组只进行假手术;于造模后第60 d处死大鼠,评价HGF对血尿素氮、血肌酐、24 h尿蛋白、肾系数等肾功能指标的改善作用,并对肾纤维化进行组织学评价。结果:与正常对照组相比,模型组肾功能下降,肾系数(8.8±0.95 g/kg)、血尿素氮(9.4±2.61 mmol/L)、血肌酐(42±10.33μmol/L,P<0.05)及24 h尿蛋白定量(25.78±8.66 mg,P<0.05)升高;HGF治疗组对肾功能有所改善,可缓解肾纤维化的进展。此外,本实验表明,对已纤维化肾脏直接注射HGF基因,可促进肾间质血管再生,并进一步降低肾小管间质损伤积分。结论:将HGF基因靶向导入大鼠体内可有效防治肾纤维化。     

昆虫的NF-kB信号通路

昆虫NF-kB信号通路由toll和imd两条通路组成,通过转录因子NF-kB作用于靶标基因kB位点,而调节抗菌活性物质的表达。大量实验表明它能够被细菌、真菌和病毒的侵染所激活,在昆虫体液免疫中发挥着主要作用。现就昆虫的NF-kB信号通路的主要信号元件等进行综述。     

长链多不饱和脂肪酸的替代来源——转基因油料作物

长链多不饱和脂肪酸(LCPUFA)对人体健康和发育具有极为重要的作用.由于海洋鱼类资源过度捕捞和环境污染的加剧,长链多不饱和脂肪酸的来源日益枯竭.利用转基因油料作物生产LCPUFA,特别是DHA和EPA成为目前研究的热点.归纳了LCPUFA合成代谢途径相关基因的最新研究进展,描述了利用植物基因工程合成长链多不饱和脂肪酸(特别是EPA和DHA)取得的主要成果,讨论了影响转基因油料作物合成DHA和EPA的关键因素,最后对利用转基因油料作物合成DHA和EPA的研究前景进行了展望.     

恶性肿瘤并发急性下肢深静脉血栓形成的病因分析与治疗

目的：探讨恶性肿瘤患者并发急性下肢深静脉血栓（deep vein thrombosis of the lower extremity,DVT）的形成原因、诊断要点与治疗、护理及预防措施,为相关治疗提供参考。方法：回顾性分析了我院22例恶性肿瘤并发下肢深静脉血栓患者的临床病理表现,诊断方式及采取的治疗与护理措施,所有患者采用小-中等剂量尿激酶溶栓、同时予以低分子肝素钠抗凝、低分子右旋糖酐及丹参川芎嗪注射液辅助治疗,部分患者采取切除根治手术,分析比较患者的疗效。结果：采取上述治疗后21例患者取得了满意的效果,其中1例患者经治疗半月后效果不明显,进一步检查确诊为恶性淋巴瘤,还有1例患者经治疗好转出院3个月后再次出现对侧下肢深静脉血栓,进一步检查确诊为胆管癌。结论：DVT患者经联合抗凝、溶栓、祛聚、扩血管等综合治疗效果明显,以DVT为首发表现的患者治疗效果不佳或再发应及早考虑恶性肿瘤,以免漏诊,耽误原发病的治疗。     

糖尿病性下肢缺血性血管病的外科治疗

目的:探讨糖尿病性下肢缺血性血管病的治疗方法。方法:对24例Ⅰ型糖尿病患者合并下肢动脉缺血性疾病的39条肢体体进行了手术,其中动脉旁路手术31例,占79%。对3例患者进行了下肢截肢处理。结果:接受动脉旁路手术的患者出院时动脉血流均保持通畅。一例51岁男性患者四肢肿胀、变黑,经治疗无效死亡。结论:糖尿病性缺血性血管病可以通过外科手术治疗。如下肢远端动脉旁路移植、腔内血管成型术等。外科治疗的方法正在探讨阶段,研究方法不断进展。外科治疗不仅可以挽救肢体或降低截肢平面,而且可为足部创面的愈合提供较好的营养环境,有利于创面的愈合和提高生活质量。     

足月周期的生理调控

下丘脑－垂体－卵巢轴直接调控月经周期,三者之间通过促性腺激素与卵轩体激素对下丘脑,垂体产生的反馈机制产生生理性周期变化,卵巢局部产生众多的肽关因子形成卵巢内自分泌／社分泌调节系统,参与垂体促性腺激素性腺内作用机制的调迭。     

Muscle injection of rAAV/mFIX to secrete clotting factor IX corrects the hemorrhagic tendencies in hemophilia B mice

Recombinant AAV particles of high titer (>1013 virus genome/mL) were prepared according to the rHSV/AAV helper virus method. After intramuscular injection of viral vectors in the hind limb, a sustained elevated level (>370 ng/mL) of murine FIX expression in the plasma of hemophilia B mouse was detected and persisted for more than 350 days. The biological activity reached 30% of normal levels, and bleeding symptoms in the treated mice were significantly alleviated. No anti-FIX antibody (inhibitor) was detected, though anti-AAV antibodies were found at a very low level after single injection. Repeated injection with rAAV/mFIX led to a variation in anti-AAV antibody levels between the two groups which had received different doses. Results from tissue analysis confirmed the skeletal muscle as the origin for circulating functional mFIX. Our results suggest that AAV-mediated gene transfer offers a promising method of gene therapy for hemophilia B.     

Gene therapy for hemophilia B mediated by recombinant adeno-associated viral vector with hFIXR338A, a high catalytic activity mutation of human coagulation factor IX

A mutant human factor IX with arginine at 338 residual changed to alanine (hFIXR338A) by site-directed mutagenesis was introduced into AAV vectors, and a recombinant adeno-associ- ated viral vector containing hFIXR338A, prepared by rHSV/AAV hybrid helper virus system, was directly introduced to the hind leg muscle of factor IX knock out mice. The expression and the biological activity of human factor IX mutant, hFIXR338A, and the immune response against it in the treated mice were assayed and detected. The results showed that (i) the high-level expression of human factor IX mutant protein, hFIXR338A, has been detected in rAAV-hFIXR338A treated hemophilia B mice and lasted more than 15 weeks; (ii) the clotting activity of hFIXR338A in plasma is 34.2%± 5.23%, which is remarkably higher than that of (14.27% ± 3.4%) of wild type hFIX treated mice in the activated partial thromboplastin assay; (iii) immune response against factor IX R338A was absent, with no factor IX mutant protein (hFIXR338A) inhibitors development in the treated mice; and (iv) no local or systemic side-effects and toxicity associated with the gene transfer were found. It demonstrated the potential use of treating hemophilia B by recombinant adeno-associated viral vectors with mutant hFIXR338A gene, an alternative strategy for hemophilia B gene therapy to wild-type human factor IX.